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SUMMARY 
Craving is an integral element in the understanding of alcohol dependence. Recent human and animal research 
implicates the serotonergic and dopaminergic systems in the mediation of excessive alcohol consumption. In this study, 
a cue-based approach was used to qualify and quantify craving occurring during acute withdrawal from alcohol. Fifty 
alcoholics were given either placebo, bromocriptine or fluoxetine in a randomised double-blind fashion and craving was 
sequentially measured over the next 15 days. Both fluoxetine and bromocriptine significantly attenuated total craving 
scores without similarly affecting withdrawal symptoms. The results suggest the importance of neurotransmitters in 
mediating craving. The significance of these data in the light of various behavioural and neurochemical models have 
been discussed. 
1988). Postive reinforcement (euphoria-based) 
theories perceive craving as the desire for the 
'high' induced by alcohol (Stewart et al, 1984). 
Inspite of the limitations (Drummond et al, 1990), 
these theories have established a framework for 
the understanding and experimental induction of 
craving. 
A biological basis for craving has been 
proposed from the observation that certain labo-
ratory animals voluntarily and selectively con-
sume alcohol in a manner similar to that of 
humans (Murphy et al, 1982). To explain this, all 
psychoactive drugs, including alcohol, are pro-
posed to act on 'brain-reward systems' (Wise & 
Bozarth, 1987) altering them in crucial ways to 
maintain drug use. The ventral tegmental area 
(VTA) in the ventral midbrain and its projection 
to the nucleus accumbens (NA) have been identi-
fied as the crucial brain area in reward mediation 
(Robinson & Berridge, 1993). By virtue of being 
the major neurotransmitter input, the 
mesocorticolimbic dopamine (DA) system has 
been implicated in drug reinforcement (Wise and 
Romprei, 1989) since all abusable drugs share 
the common property of selectively enhancing 
DA release in the VTA-NA areas. Alcohol has 
also been found to increase DA release in these 
regions following local or systemic application 
INTRODUCTION 
Most attempts at identifying common de-
fining feature of alcoholism have invoked the 
concept of 'craving' as a key explanatory parame-
ter. Inspite of the popularity of the term, perhaps 
due to its intuitive appeal, there is no consensual 
definition as indeed for'urges' and 'wanting' which 
have been used interchangeably (Kozlowski & 
Wilkinson, 1987). Current consensus regards crav-
ing as a non-specific vector connected to the 
subjective desire to take drugs (Tiffany, 1990). It 
does not by itself define the various states that 
can potentially activate the desire. 
In the search for the determinants of crav-
ing, the cue reactivity paradigm has been exten-
sively used. This approach has demonstrated that 
for a group of alcoholics, various internal and 
external drug-related cues induce autonomic arousal 
(Glautier & Drummond, 1994). However, the 
subjective report of craving is a less consistent 
finding thus casting doubt on the proposed linear 
relationship between arousal, craving and drug 
intake. Conditioning theories have traditionally been 
used to explain these results. Briefly, negative 
reinforcement (withdrawal-based) models view 
craving as a desire of relief from distressing overt 
or covert withdrawal symptoms (Koob and Bloom, 
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(Signs et al, 1992). In addition, DA agonists like 
bromocriptine have been found to attenuate drink-
ing in animals and reduce craving in human sub-
jects (Dongier et al, 1991) suggesting a strong 
dopaminergic modulation of the need to drink. 
The serotonergic (5HT) system has also 
been implicated in the voluntary consumption of 
alcohol (Lemarquand et al, 1994). Various phar-
macological manipulations increasing brain SHT 
have been found to reduce consumption in animal 
models (Lu et al, 1993). Similarly, the use of 
specific serotonergic reuptake inhibitors (SSRI) 
like fluoxetine and zimeldine (Amit et al, 1991) 
have been observed to reduce craving and 
subesequent alohol consumption in humans. All 
this suggests that hypofunctioning of die SHT 
system may be relevant to the experience of 
craving. 
The current study, based on the above 
findings, seeks to examine the effects of DA and 
5HT function enhancement during acute with-
drawal from alcohol. The hypothesis made was 
that augmentation of DA and SHT by appropriate 
pharamacological tools would reduce craving. 
METHOD 
Subjects for the study were chosen from 
males presenting to the outpatient facilities of 
NIMHANS, Bangalore. After screening, prospec-
tive subjects were referred to assess eligibility of 
participation. 
The following inclusion criteria were used 
to generate a relatively homogeneous population: 
1.After a detailed clinical interview with 
die subject and a key relative, all patients had to 
unambiguously fulfill diagnostic criteria for alco-
hol - dependence , as in the DSM - IIIR (APA, 
1987). 
2.Subjects had to be in the age group of 18 
- 45 Years. 
3. Only subjects presenting with simple 
withdrawal were chosen. To facilitate measure-
ment and ensure drug compliance, subjects had 
to agree to be inpatients during the study period. 
4. The manifestations of withdrawal from 
alchohol are 'time limited'. To acheive uniformity 
of measurement, all subjects had their last drink 
within 24 hours of participation in this study. 
5. Presence of cognitive deficits was meas-
ured by the MMSE (McHugh & Folstein, 1978). 
Only subjects scoring above the suggested cut -
off were selcted. 
6. Presence of concurrent depression and 
anxiety disorders was specifically sought for in 
the clinical interview. Only subjects without at 
obvious'co - morbid depression anxiety were 
chosen. 
7. Only subjects without serious alcohol -
induced medical complications, as assessed by a 
detailed clinical examination and relevant investi-
gations, were included in the trial. 
Information regarding current age, age of 
onset, duration of drinking and the duration of 
dependence was also collected since each of 
these could affect the severity of the withdrawal 
reaction. The rationale of the study was also 
explained to the subjects and informed consent 
for participation obtained. 
Measurement of craving 
In view of the many limitations inherent in 
the measurement of craving, 33 alcoholics were 
asked about common internal and external corre-
lates of the perceived subjective desire to drink 
during the experience of withdrawal. After con-
tent - analysis, the 10 most common responses 
were identified. These included various interna) 
subjective states as well as cues related to the 
environment. These items together formed the 
Scale for assessment of alcohol withdrawal • 
related craving (see Appendix). To quantify the 
severity of each item, a ten - point subject - rated 
visual analogue scale was used. 
Measurement of withdrawal 
The phenomenology and severity of with-
drawal was assessed by the Scale for alcohol 
withdrawal. This is a 22 - item instrument, and 
each item is graded on a 0-3 scale of severity. 
In keeping with the hypothesis, fluoxetine 
and bromocriptine were choten tsy explore the 
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effects of 5HT and DA system perturbation on 
experienced craving. 
STUDYDESIGN 
Subjects were randomly allocated to any 
one of three groups receiving either fluoxetine, 
bromocriptine or placebo. Fluoxetine was used at 
a dose of 40 mg/day, while 5 mg of bromocriptine 
was administered and glucose powder was the 
placebo. All groups were given the drugs thrice a 
day in identical capsules. The active drugs were 
adminstered in the morning and afternoon with 
the night dose being a placebo capsule. The allo-
cation of patients and subsequent drug adminis-
tratis! was done in a double blind fashion. 
6b pay 0, both withdrawal and craving -
scale items were administered and rated. After 
this , drugs Were started and continued for the 
next IS daysTScale items were assessed each day 
and those found positive were rated for severity. 
STATISTICAL TECHNIQUES 
1. Descriptive statistical measures like mean 
and SD were used to describe pre - treatment 
sample characteristics. 
2. Two-way ANOVA (days x drugs) were 
performed for each item and for the total craving 
scores between the three groups. i: 
•* 
3. The craving - scale items were subject-
ed to principal component analysis with varimax 
rotation to generate higher - order factors. 
4. Two - way ANOVA was also performed 
for total withdrawal - scores between the three 
groups. 
5. Post - hoc Fisher's ¥ - test of signifi-
cance was carried out for each craving - scale 
item. 
6. Correlation analysis was done between 
craving and withdrawal items on Day 0. 
RESULTS 
After initial screening , SO subjects en-
tered the trial. On opening the blind the group 
receiving the placebo had 18 subjects, whereas 
the groups receiving fluoxetine and bromocriptine 
had 16 subjects each. 
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Table 1 displays the pretreatment values 
of variables like age , age of onset of drinking , 
duration of alcohol use and duration of depend-
ence. There were no significant differences on 
any of these variables across the guoups. 
The principal component analysis of die 
craving - scale items (Table 2) led to the emer-
gence of three meaningful principal components 
which together explained 61.2 % of the variance. 
These were labelled as (1) restoration of bodily 
comfort, (2) alleviation of negative mood state 
and (3) responsivity to external cues. 
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Table II 
Principal components analysis of craving-scale items 
with varimax rotation. 
Item 
1. Morning 
2. Thirst 
3. Fatigue 
4. Irritability 
5. Anxiorysis 
6. Insomnia 
7. Wine store 
8. Tremors 
9. Smoking 
10. Food 
Evols 
38.82 
13.32 
10.71 
9.38 
7.86 
6.75 
4.76 
3.29 
2.83 
2.24 
PCI: 
Weights 
0.39 
0.31 
0.35 
0.17 
0.39 
0.24 
0.18 
0.37 
0.37 
0.21 
PC 2: 
Weights 
0.16 
0.08 
0.10 
0.61 
0.61 
0.16 
0.26 
0.22 
0.25 
0.02 
PC3: 
Weights 
0.33 
0.08 
0.27 
0.27 
0.27 
0.26 
0.32 
0.05 
0.38 
0.65 
The three principal components that emerged were: 
1. Restoration of bodily comfort 
2. Alleviation of negative mood state 
3. Responsiveness to external cues 
Table III 
Two-way ANOVA for individual craving-scale items 
Item 
1. Morning 
2. Thirst 
3. Fatigue 
4.lrri1abity 
5.Anxiorysis 
6. Insomnia 
7. Wine store 
8. Tremors 
9. Smoking 
10. Food 
Drug 
f 
115.83 
18.93 
80.33 
5.35 
102.58 
91.76 
5.87 
104.55 
40.97 
3.36 
P* 
0.001 
0.001 
0.001 
0.005 
0.001 
0.001 
0.003 
0.001 
0.001 
0.035 
Days 
f 
206.87 
51.50 
180.59 
22.46 
157.72 
107.39 
53.89 
235.76 
36.82 
35.86 
P* 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
Interaction 
f 
7.28 
1.73 
6.07 
1.40 
6.16 
6.30 
2.00 
5.75 
2.69 
0.67 
P* 
0.001 
0.009 
0.001 
0.076 
0.001 
0.001 
0.001 
0.001 
0.001 
0.910 
* Significance at P < 0.001 Degrees of freedom: 2,49 
The two- way ANOVA scores for individ-
ual craving - scale items are displayed in Table 3 
.The items showing statistically significant day x 
drug interactions tapped craving related to early 
morning hangovers, fatigue, anxiolysis, insom-
nia, tremors and in respones to pleasurable exter-
nal cues like preferred wine store and smoking. 
The total craving - scores between the 
groups are shown in Figure 1. Figure 2. graphi-
cally depicts total scores for the withdrawal items. 
FIGURE I: TOTAL CRAVING SCORES 
PLACEBO 
DAY 
BROMOCRIPTINE -•— FLUOXETINE 
FIGURE II: TOTAL WITHDRAWAL SCORES 
PLACEBO  BROMOCRIPTINE — FLUOXETINE 
The correlation analysis of craving - and 
withdrawal - scale items was performed for Day 
0 to understand the extent of overlap of the 
constructs (data not shown, available on re-
quest). The only meaningful correlations oc-
curred between irritability as a cue and with-
drawal symptoms of insomnia, restless sleep, 
tremors and dehydration. 
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DISCUSSION 
In this study, we chose to investigate crav-
ing occurring during withdrawal as it is consist-
ent , vivid and therfore , more amenable to meas-
urement. Secondly , the potential effects of drugs 
are expected to be more comprehensible since 
neurotansmitter changes during withdrawal have 
already been relatively well documented (Nutt and 
Glue, 1986). 
There is a lack of consensus regarding 
which strategy best identifies craving. In view of 
this , a 'bottom - up' approach was chosen with 
alcoholics' self - reports forming the basis for the 
measurement of craving . This ensures that the 
dimensions of craving are tapped adequately as 
demonstrated by adequate face validity and 
sensitvity of the craving -scale items. 
To generate higher - order factors which 
are closer to the psychological structure of crav-
ing, multivariate statistics like principal compo-
nents analysis were used. To this end three clini-
cally meaningful factors explaining 61.2% of the 
variance were generated. Factor 1 (restoration of 
physical comfort) and Factor 2 (alleviation of 
negative mood) could conceptually be collapsed 
into a single 'releif from distress' factor. Factor 3, 
however, was more closely linked to the positive 
expectancy effects of alcohol. 
A large body work sees craving as arising 
predominantly from the substrate of withdrawal 
distress (Laberg & Ellertsen, 1987). Alcohol, by 
removing this distress, has been thought to have a 
negative reinforcing relationship with craving. In 
view of the current study being conducted during 
acute withdrawal, this negative reinforcement re-
lationship was expectedly observed especially with 
cues tapping the physical symptoms of with-
t drawal. 
Positive expectancy-related cues, as a de-
terminant of craving occurring during a period of 
distress, is an interesting finding. It suggests that 
the desire for euphorogenic effects of alcohol are 
intermingled with, but independent of, the need to 
relieve distress. The opponent-process theory of 
alcohol use can explain this observation best 
(Donovon & Chaney, 1985). This theory sug-
gests that drugs simultaneously elicit mutually 
inhibitory agonist and antagonist responses. De-
pending on the context, any one response could 
assume a greater, but not exclusive, role in deter-
mining further drinking. Since withdrawal-relat-
ed craving was studied, it explains both why 
drug antagonistic (withdrawal) cues assume 
greater importance and how agonist (euphoric) 
responses could coexist. 
It is noteworthy that a large part of the 
variance of the observed results remained unex-
plained. Conceivably, this could be a function of 
the study setting, quality of therapeutic alliance, 
sick-role expectations and personality variables. 
None of these have been adequately studied and 
remain an important area for further research. 
The double-blind design of the study, use 
of a placebo group, clear specification of the 
dependent status, prevention of drop-outs and 
adequate compliance with experimental drugs 
are in keeping with the expected methodological 
standards (Moskowit/, 1983). In addition, the 
pre-treatment variables were homogeneously dis-
tributed across groups thus increasing the ro-
bustness of the findings. 
The incorporation of the placebo group 
makes naturalistic observation of the patterns of 
withdrawal and craving possible. As seen in Dia-
grams 1 and 2, total scores decline in a fairly 
similar fashion. However, both active drugs af-
fected craving and withdrawal differentially. Both 
bromocriptine and fluoxetine produce significantly 
greater detriment of craving scores as compared 
to the effects on withdrawal symptoms. Again, 
between drugs, unlike in withdrawal, fluoxetine 
produced greater effects between days 3 to 9 on 
total craving scores. This dissociation of drug 
effects on craving and withdrawal suggest that 
the neurobiological substrates of craving are dis-
tinct from those mediating withdrawal. Moreo-
ver, correlation analysis between craving- and 
withdrawal- scale items, done on Day O, do not 
show significant overlap, again suggesting their 
relative independence. CRAVING IN ALCOHOL WITHDIRAWAL 
There is a large body of evidence linking 
5HT dysfunction and alcohol consumption. 
Preclinical studies have mostly shown an inverse 
relationship betweerralcohol preference and 5HT 
levels have been demostrated in crucial brain 
areas like the VTA and NA in alcohol-preferring 
rats even before exposure to alcohol (Murphy et 
al, 1982). Interestingly, alcohol increases 5HT in 
these areas following both acute and chronic 
exposure, prompting the self medication hypothe-
sis of alcohol use (Haleem 1990). Clinical exten-
sion of these results with various SSRIs which 
increase synaptic availabilityof 5HT are found to 
attenuate craving and alcohol consumption (Gill 
&Amit, 1989). 
This study adds to the growing body of 
research linking 5HT and craving. It confirms 
that the postulated inverse relationship holds true 
even during withdrawal. During acute withdraw-
al, there is a fall in 5HT levels in the absence of 
alcohol (Yamamura et al, 1992). This is probably 
corrected by fluoxetine by producing a specific 
increase of 5HT in a non-selective manner. The 
rapid onset of action would suggest that these are 
independent of fluoxetine's anti-depressant ef-
fect. The significantly greater efficacy of fluoxetine 
would argue against the proposed indirect en-
hancement of DA in the brain-reward areas as 
being the primary mode of action (Blandina et al, 
1989). 
Specific 5HT enhancement thus emerges 
as the most probable mechanism of fluoxetine's 
ability to reduce craving. The next logical phase 
of research would be to identify which speicific 
5HT receptor sybtypes mediate this effect. The 
5HT3 receptor has emerged as a likely candidate 
in this regard (Grant & Barrett, 1991). Similarly, 
the demonstration that m-chlorophenyl papaverine 
(mCPP), a 5HT agonist with some spicificity for 
5HT2a and 5HT2c receptors, could elicit and 
alcohol-like high in abstinent subjects is a direct 
demonstration of the link between 5HTand crav-
ing (Krystal et al, 1994). This approach would 
also clarify whether 5HT deficits in alcoholism 
are unique to the disorder or is a more general 
marker of psychopathology as has been suggest-
ed (Virkkunen et al, 1994). 
The other hypothesis made was that 
bromocriptine by its specific D2 agonism would 
reduce craving. This has also been substantiated 
by the results of this study. Neuroleptic-induced 
dysphoria and related animal work have suggest-
ed that DA mediates hedonic properties of cues. 
This is acheived by attribution of positive sali-
ence thus making these cues more attractive and 
wanted (Robbins & Everitt, 1992). As an extesion 
of this, drugs are supposed to be reinforcing 
because of their property of increasing DA in 
brain-reward areas. During the process of with-
drawal, there is a global reduction of DA 
(Kuriyama & Okhuma, 1991) probably produc-
ing distress and therefore craving. Accoriding to 
this hypodopaminergic theory of craving, 
bromocriptine probably produces its effects by 
substituting for the lowered DA. 
Direct DA agonism, inspite of its strong 
theoretical link with drug use, was found to be 
less effective than fluoxetine at least initially. The 
reason for this remains unclear. It might be a 
consequence of the dose of bromocriptine used 
(5 mg/day) which would cause D2 autoreceptor 
stimulation, thus lessening the magnitude of post-
synaptic agonistic effects (Fuxe et al, 1981). 
In conclusion, this study measures crav-
ing in relation to withdrawal from alcohol and 
explores the effect fluoxetine and bromocriptine 
have on it. It also adds to the evidence linking 
craving and certain monoamine (DA and 5HT) 
levels. In addition to discussing the possible mech-
anisms underlying these findings, this work sug-
gests new approaches for a more comprehensive 
understanding and probable therapeutic manipu-
lation of the compelling experience of drug crav-
ing. 
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APPENDIX 
1. When you wake up in the morning with 
a hangover, do you feel like having a drink imme-
diately ? 
2. When you are feeling hot and thirsty, 
does the thought of having a drink come to 
mind? 
3. When you are tired and exhausted, do 
you want a drink to feel better ? 
4. Whenever you are angry with some-
body, do you have the urge to drink at once ? 
5. When feeling tense and anxious, do you 
feel like having a drink? 
6. When unable to sleep at night, do you 
have a strong wish to drink ? 
7. When you see your usual wine store, do 
you feel attracted towards it for a quick drink ? 
8. When your hands shake, does the 
thought of a drink come to mind ? 
9. While smoking, do you also experience 
the desire to drink ? 
10. Just before your favourite meal, do 
you get an urge to drink ? 
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